<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03386448</url>
  </required_header>
  <id_info>
    <org_study_id>701</org_study_id>
    <nct_id>NCT03386448</nct_id>
  </id_info>
  <brief_title>The Safety and Efficacy of Naltrexone and Scopolamine Utilized in the Treatment of Major Depression</brief_title>
  <official_title>The Safety and Efficacy of Naltrexone and Scopolamine Utilized in Combination in the Treatment of Major Depression: A Double Blinded, Randomized, Controlled Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Taub Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Taub Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to determine the safety and efficacy of scopolamine
      utilized in conjunction with naltrexone for the treatment of major depression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be a double blinded, randomized controlled trial. The medications will be
      administered orally. The sample size will be 40 participants, 20 in the treatment group and
      20 in the control group. The study period will be 4 weeks. Eligible participants will have
      major depression by history for at least 8 weeks, between 18-65 years old, and in generally
      good health other than depression. The MADRS questionaire will be utilized to determine the
      response to the medications.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">March 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double blinded, randomized, controlled parallel design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>The participants and physician are both blinded to medication vs. control medication</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>response to medications</measure>
    <time_frame>4 weeks</time_frame>
    <description>The Montgomery-Asberg (MADRS) depression scale will be utilized throughout the study. The scale is scored 0-60, 0 signifying no depression symptoms and 60 signifying very severe depression. A diagnosis of depression will be given to a participant in this study for a MADRS score of 20 or greater. A clinical response to medication will be noted when a participant has a 25% or greater decrease in MADRS score during the trial.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>participants will receive active medications scopolamine and naltrexone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Scopolamine and naltrexone</intervention_name>
    <description>participants will receive scopolamine and naltrexone in buccal drops</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo arm</intervention_name>
    <description>participants will receive placebo medications</description>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or female, aged 18-65

          -  in good health other than major depression for 8 weeks or more

          -  negative pregnancy test

          -  able to comply with instructions

          -  able to provide informed consent

        Exclusion Criteria:

          -  pregnant or lactating

          -  danger to self or others

          -  severe kidney or liver disease

          -  schizophrenia

          -  allergy to scopolamine or naltrexone

          -  glaucoma

          -  Monoamine oxidase (MAO) inhibitor use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neal Taub</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Taub Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Neal S Taub, MD</last_name>
    <phone>7049573391</phone>
    <email>nealtaub@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shelley H Hagerty, BA</last_name>
    <phone>7044429805</phone>
    <email>shagerty@taubmd.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Taub Group</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neal Taub</last_name>
      <phone>704-957-3391</phone>
      <email>nealtaub@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Shelley Hagerty</last_name>
      <phone>7044429805</phone>
      <email>shagerty@taubmd.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2017</study_first_submitted>
  <study_first_submitted_qc>December 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2017</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Taub Group</investigator_affiliation>
    <investigator_full_name>Neal Taub</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Scopolamine Hydrobromide</mesh_term>
    <mesh_term>Butylscopolammonium Bromide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

